
Reimbursement is still dependent on authorisation and benefit limits.
Some drugs included:
ANTIHEMORRHAGICS
Hemlibra
CARDIOVASCULAR SYSTEM
Volibris
DERMATOLOGICALS
Dupixent
ANTIVIRALS FOR SYSTEMIC USE
Epclusa
ANTINEOPLASTIC AGENTS
Blitzima and Ristova (Rituximab)
Plegridy
IMMUNOSUPPRESSANTS
Myelenea and Filengia (Fingolimod)
Unamity
Tremfya
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xolair
Recent Posts
Dutch Elderly Care Challenges: Navigating Fragmentation in Support Systems
A recently published visualization from Zorginstituut Nederland illustrates the intricate pathways through which an elderly individual with progressive dementia, such as Mrs. Mahabier, encounters multiple statutory frameworks, care providers, and administrative entities as her needs evolve. It de...
Compliance Challenges Under the New Procurement Regulations South Africa for Health Sector Suppliers
South Africa’s Draft General Public Procurement Regulations, 2026 establish a comprehensive framework that prioritises transparency, accountability and value for money in all public contracts under procurement regulations South Africa. For pharmaceutical, biotech and medtech companies bidding on ...
Preferential Procurement Regulations: Impact on Health Sector Suppliers in 2026
South Africa’s Preferential Procurement Regulations, embedded in the Draft General Public Procurement Regulations, 2026, introduce mandatory set-asides, pre-qualification tests and subcontracting thresholds that directly affect suppliers of active pharmaceutical ingredients, diagnostics and hospi...